曼恩凯德生物医疗(MNKD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MNKD 曼恩凯德生物医疗

已收盘 01-06 16:00:00 EST

5.62

+0.00

0.00%

盘后5.70

+0.08+1.42%

19:55 EST

最高5.76	最低5.55	成交量299.58万
今开5.56	昨收5.62	日振幅3.74%
总市值17.26亿	流通市值16.92亿	总股本3.07亿
成交额1,691万	换手率1.00%	流通股本3.01亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MNKD","market":"US","secType":"STK","nameCN":"曼恩凯德生物医疗","latestPrice":5.62,"timestamp":1767733200000,"preClose":5.62,"halted":0,"volume":2995797,"hourTrading":{"tag":"盘后","latestPrice":5.7,"preClose":5.62,"latestTime":"19:55 EST","volume":83155,"amount":467404.9032,"timestamp":1767747345045},"delay":0,"floatShares":300981629,"shares":307070281,"eps":0.097891,"marketStatus":"已收盘","change":0,"latestTime":"01-06 16:00:00 EST","open":5.56,"high":5.76,"low":5.55,"amount":16905150.655931998,"amplitude":0.037367,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.097891,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1767776400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1090987200000,"exchange":"NASDAQ","adjPreClose":5.62,"preHourTrading":{"tag":"盘前","latestPrice":5.56,"preClose":5.62,"latestTime":"09:29 EST","volume":3080,"amount":17137.08612,"timestamp":1767709799999},"postHourTrading":{"tag":"盘后","latestPrice":5.7,"preClose":5.62,"latestTime":"19:55 EST","volume":83155,"amount":467404.9032,"timestamp":1767747345045},"volumeRatio":1.160497,"impliedVol":0.4628,"impliedVolPercentile":0.44},"requestUrl":"/m/hq/s/MNKD","defaultTab":"news","newsList":[{"id":"1172067255","title":"曼恩凯德生物医疗宣布美国FDA接受其Furoscix Readyflow™自动注射器的补充新药申请审查，针对慢性心力衰竭或慢性肾病成人水肿的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1172067255","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172067255?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:08","pubTimestamp":1764594489,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，美国FDA已接受其Furoscix Readyflow™自动注射器的补充新药申请审查，该药物用于治疗慢性心力衰竭或慢性肾病成人的水肿。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","BK4139"],"gpt_icon":0},{"id":"1169320260","title":"曼恩凯德生物医疗股价在盘前交易中下跌5.7%，因公司决定中止肺病治疗的第三阶段临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1169320260","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169320260?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:15","pubTimestamp":1762780554,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗的股价在盘前交易中下跌5.7%，原因是公司宣布将中止针对肺病治疗的第三阶段临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","BK4139"],"gpt_icon":0},{"id":"1197762624","title":"异动解读 | 曼恩凯德生物医疗盘前大跌6.93%，三期临床试验结果令人担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1197762624","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197762624?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:08","pubTimestamp":1762780104,"startTime":"0","endTime":"0","summary":"周一（11月10日）盘前，曼恩凯德生物医疗（MNKD）股价大跌6.93%，引发投资者关注。\n\n据悉，曼恩凯德生物医疗在其三期ICON-1临床试验中未观察到转化情况，这引发了市场对公司能否实现研究主要终点的担忧。这一消息对公司股价造成了明显的负面影响。\n\nICON-1试验是曼恩凯德生物医疗的一项重要研究，其结果可能对公司未来的药物开发和市场前景产生重大影响。未能观察到预期的转化情况意味着试验可能无法达到预设的主要终点，这可能会影响到新药的审批进程和公司的长期发展战略。投资者对这一不利消息反应强烈，导致公司股价在盘前交易中出现大幅下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MNKD"],"gpt_icon":0},{"id":"1128732960","title":"MannKind：在三期ICON-1试验中未观察到转化情况，因而对实现研究主要终点的可能性产生担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1128732960","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128732960?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:06","pubTimestamp":1762779992,"startTime":"0","endTime":"0","summary":"MannKind：在三期ICON-1试验中未观察到转化情况，因而对实现研究主要终点的可能性产生担忧","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MNKD","BK4139"],"gpt_icon":0},{"id":"1172790881","title":"曼恩凯德生物医疗宣布美国FDA接受审查其针对4-17岁糖尿病儿童及青少年吸入胰岛素Afrezza的补充生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1172790881","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172790881?lang=zh_cn&edition=full","pubTime":"2025-10-13 20:05","pubTimestamp":1760357117,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，美国食品药品监督管理局（FDA）已接受审查该公司提交的补充生物制品许可申请（sBLA），该申请涉及其吸入胰岛素产品Afrezza在4-17岁糖尿病儿童和青少年患者中的应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4584","MNKD"],"gpt_icon":0},{"id":"1191122080","title":"曼恩凯德生物医疗完成收购scPharmaceuticals，推动心脏代谢护理业务收入快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1191122080","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191122080?lang=zh_cn&edition=full","pubTime":"2025-10-07 21:02","pubTimestamp":1759842174,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗完成收购scPharmaceuticals，推动心脏代谢护理业务收入快速增长","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNKD","BK4584"],"gpt_icon":0},{"id":"1135181145","title":"曼恩凯德生物医疗收购scPharmaceuticals 加速营收增长并成为心脏代谢和肺部疾病领域以患者为中心的领导者","url":"https://stock-news.laohu8.com/highlight/detail?id=1135181145","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135181145?lang=zh_cn&edition=full","pubTime":"2025-08-25 19:31","pubTimestamp":1756121507,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗收购scPharmaceuticals，加速营收增长并成为心脏代谢和肺部疾病领域以患者为中心的领导者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCPH","BK4584","BK4007","BK4139","MNKD"],"gpt_icon":0},{"id":"2557538673","title":"美股财报 | 曼恩凯德生物医疗发布Q2财报 前半年累计净利润同比增长60.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557538673","media":"同花顺iNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557538673?lang=zh_cn&edition=full","pubTime":"2025-08-07 12:00","pubTimestamp":1754539215,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗发布Q2财报，2025财年前六月累计收入1.55亿美元，去年同期累计收入为1.39亿美元，同比增长11.71%。Mannkind Corporation是一家生物制药公司，侧重于诸如糖尿病和癌症之类疗法和药品的开发、研制和推广。该公司的主导候选产品——AFREZZA吸入粉末，是一种超速效胰岛素，处于后期临床研究阶段，用于成人1型或2型糖尿病高血糖的控制治疗。AFREZZA是由该公司的专有技术圈颗粒加载到胰岛素分子里。这些加载的粒子雾化吸入后，会深入到使用AFREZZA吸入器的肺部。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807120602a6d7e0d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807120602a6d7e0d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD"],"gpt_icon":0},{"id":"1177120269","title":"异动解读 | 曼恩凯德生物医疗盘后大涨6.49%，尽管季度业绩略低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1177120269","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177120269?lang=zh_cn&edition=full","pubTime":"2025-08-07 07:31","pubTimestamp":1754523078,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗在周三盘后交易中股价大涨6.49%，尽管公司公布的季度业绩略低于分析师预期。这一意外的股价上涨引起了投资者的广泛关注。根据公司发布的财报，截至6月30日的季度，曼恩凯德实现收入7653万美元，同比增长5.7%，但略低于分析师预期的7860万美元。尽管业绩未达预期，但投资者似乎对公司的整体表现持乐观态度，特别是考虑到其收入的持续增长。值得注意的是，尽管当前季度股价上涨，曼恩凯德今年迄今为止的股价仍下跌了37.9%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MNKD"],"gpt_icon":0},{"id":"1123447868","title":"异动解读 | 曼恩凯德生物医疗季度业绩不及预期，股价盘中大跌12.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123447868","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123447868?lang=zh_cn&edition=full","pubTime":"2025-08-06 22:19","pubTimestamp":1754489979,"startTime":"0","endTime":"0","summary":"周三盘中，曼恩凯德生物医疗股价大跌12.16%，主要原因是公司公布的季度业绩未能达到分析师预期。根据公司最新发布的财报，截至6月30日的季度，曼恩凯德生物医疗实现收入7653万美元，同比增长5.7%，但低于分析师预期的7860万美元。这一业绩表现明显低于市场预期，导致投资者信心受挫。事实上，曼恩凯德生物医疗股价今年以来已下跌37.9%，显示出公司面临的持续压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MNKD"],"gpt_icon":0},{"id":"2551184462","title":"曼恩凯德生物医疗盘中异动 早盘股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551184462","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551184462?lang=zh_cn&edition=full","pubTime":"2025-07-14 21:41","pubTimestamp":1752500465,"startTime":"0","endTime":"0","summary":"北京时间2025年07月14日21时41分，曼恩凯德生物医疗股票出现波动，股价快速上涨5.17%。截至发稿，该股报3.97美元/股，成交量24.9508万股，换手率0.08%，振幅5.17%。机构评级方面，在所有7家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为0.03%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071421410597a5bf0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071421410597a5bf0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4584","MNKD"],"gpt_icon":0},{"id":"2550659640","title":"曼恩凯德生物医疗盘中异动 早盘急速拉升5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550659640","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550659640?lang=zh_cn&edition=full","pubTime":"2025-07-09 22:53","pubTimestamp":1752072838,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日22时53分，曼恩凯德生物医疗股票出现异动，股价快速拉升5.11%。截至发稿，该股报3.81美元/股，成交量82.6153万股，换手率0.27%，振幅4.70%。机构评级方面，在所有7家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为1.18%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709225358953c4782&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709225358953c4782&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4584","MNKD"],"gpt_icon":0},{"id":"2548882807","title":"曼恩凯德生物医疗盘中异动 临近收盘快速下跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548882807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548882807?lang=zh_cn&edition=full","pubTime":"2025-07-02 03:37","pubTimestamp":1751398642,"startTime":"0","endTime":"0","summary":"北京时间2025年07月02日03时37分，曼恩凯德生物医疗股票出现波动，股价大幅下挫5.08%。截至发稿，该股报3.55美元/股，成交量412.319万股，换手率1.36%，振幅5.88%。机构评级方面，在所有7家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为0.47%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507020337239532ee65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507020337239532ee65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","BK4139","MNKD"],"gpt_icon":0},{"id":"2516548098","title":"曼恩凯德生物医疗2024财年实现净利润27.59百万美元，同比增加331.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548098","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516548098?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931288,"startTime":"0","endTime":"0","summary":"3月3日，曼恩凯德生物医疗公布财报，公告显示公司2024财年净利润为27.59百万美元，同比增加331.07%；其中营业收入为2.86亿美元，同比增加43.72%，每股基本收益为0.10美元。从资产负债表来看，曼恩凯德生物医疗总负债4.73亿美元，其中短期债务13.12百万美元，资产负债比为0.84，流动比率为0.04。机构评级：截至2025年3月3日，当前有7家机构对曼恩凯德生物医疗目标价做出预测，其中目标均价为10.00美元，其中最低目标价为9.00美元，最高目标价为12.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000215abe4acf9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000215abe4acf9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD"],"gpt_icon":0},{"id":"2514385666","title":"曼恩凯德生物医疗盘中异动 早盘股价大跌5.21%报5.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385666?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666711,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分，曼恩凯德生物医疗股票出现异动，股价急速下挫5.21%。截至发稿，该股报5.19美元/股，成交量16.1874万股，换手率0.05%，振幅7.31%。曼恩凯德生物医疗股票所在的生物技术行业中，整体涨幅为0.06%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722315198951016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722315198951016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","BK4139","MNKD"],"gpt_icon":0},{"id":"2514585227","title":"曼恩凯德生物医疗盘中异动 股价大跌5.13%报5.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514585227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514585227?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:45","pubTimestamp":1740584740,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时45分，曼恩凯德生物医疗股票出现波动，股价快速下挫5.13%。截至发稿，该股报5.36美元/股，成交量90.4853万股，换手率0.33%，振幅4.51%。机构评级方面，在所有7家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.01%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226234540abddfef8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226234540abddfef8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4584","BK4139"],"gpt_icon":0},{"id":"2508144336","title":"曼恩凯德生物医疗盘中异动 早盘急速跳水5.01%报5.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508144336?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:49","pubTimestamp":1738594187,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时49分，曼恩凯德生物医疗股票出现波动，股价急速跳水5.01%。截至发稿，该股报5.50美元/股，成交量45.284万股，换手率0.16%，振幅2.25%。最近的财报数据显示，该股实现营业收入70.08百万美元，净利润11.55百万美元，每股收益0.04美元，毛利52.06百万美元，市盈率69.00倍。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.34%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020322494798797234&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020322494798797234&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","MNKD","BK4139"],"gpt_icon":0},{"id":"2495478508","title":"曼恩凯德生物医疗盘中异动 股价大跌5.06%报6.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2495478508","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495478508?lang=zh_cn&edition=full","pubTime":"2024-12-31 04:38","pubTimestamp":1735591125,"startTime":"0","endTime":"0","summary":"北京时间2024年12月31日04时38分，曼恩凯德生物医疗股票出现异动，股价急速下跌5.06%。截至发稿，该股报6.48美元/股，成交量151.569万股，换手率0.55%，振幅4.11%。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为1.29%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231043845a20f77da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231043845a20f77da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4584","BK4139"],"gpt_icon":0},{"id":"2492444009","title":"曼恩凯德生物医疗盘中异动 早盘股价大涨5.16%报6.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492444009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492444009?lang=zh_cn&edition=full","pubTime":"2024-12-20 22:37","pubTimestamp":1734705463,"startTime":"0","endTime":"0","summary":"北京时间2024年12月20日22时37分，曼恩凯德生物医疗股票出现波动，股价快速上涨5.16%。截至发稿，该股报6.63美元/股，成交量51.8372万股，换手率0.19%，振幅4.60%。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.25%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220223743ab8767a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220223743ab8767a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","BK4139","MNKD"],"gpt_icon":0},{"id":"2492184919","title":"曼恩凯德生物医疗盘中异动 股价大涨5.06%报6.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492184919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492184919?lang=zh_cn&edition=full","pubTime":"2024-12-18 22:53","pubTimestamp":1734533614,"startTime":"0","endTime":"0","summary":"北京时间2024年12月18日22时53分，曼恩凯德生物医疗股票出现异动，股价快速上涨5.06%。截至发稿，该股报6.23美元/股，成交量52.322万股，换手率0.19%，振幅2.85%。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。曼恩凯德生物医疗股票所在的生物技术行业中，整体跌幅为0.48%。曼恩凯德生物医疗公司简介：MannKind Corp是一家生物制药公司。该产品由小型便携式吸入器提供的人胰岛素干粉制剂组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121822533595ea554e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121822533595ea554e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MNKD","BK4139","BK4584"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mannkindcorp.com","stockEarnings":[{"period":"1week","weight":-0.026},{"period":"1month","weight":-0.0106},{"period":"3month","weight":-0.0053},{"period":"6month","weight":0.4712},{"period":"1year","weight":-0.1327},{"period":"ytd","weight":-0.0088}],"compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.003},{"period":"3month","weight":0.0278},{"period":"6month","weight":0.102},{"period":"1year","weight":0.1618},{"period":"ytd","weight":0.0085}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mannkind Corporation于1991年2月14日在美国特拉华州注册成立。Mannkind Corporation是一家生物制药公司，侧重于诸如糖尿病和癌症之类疗法和药品的开发、研制和推广。该公司的主导候选产品——AFREZZA吸入粉末，是一种超速效胰岛素，处于后期临床研究阶段，用于成人1型或2型糖尿病高血糖的控制治疗。AFREZZA是由该公司的专有技术圈颗粒加载到胰岛素分子里。这些加载的粒子雾化吸入后，会深入到使用AFREZZA吸入器的肺部。糖尿病是一个重大的健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.036288},{"month":2,"riseRate":0.380952,"avgChangeRate":-0.008021},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.010428},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.026679},{"month":5,"riseRate":0.52381,"avgChangeRate":0.106402},{"month":6,"riseRate":0.52381,"avgChangeRate":0.055192},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.056921},{"month":8,"riseRate":0.454545,"avgChangeRate":0.016248},{"month":9,"riseRate":0.681818,"avgChangeRate":0.078908},{"month":10,"riseRate":0.5,"avgChangeRate":-0.035124},{"month":11,"riseRate":0.409091,"avgChangeRate":0.019784},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.013619}],"exchange":"NASDAQ","name":"曼恩凯德生物医疗","nameEN":"MannKind"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"曼恩凯德生物医疗(MNKD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供曼恩凯德生物医疗(MNKD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"曼恩凯德生物医疗,MNKD,曼恩凯德生物医疗股票,曼恩凯德生物医疗股票老虎,曼恩凯德生物医疗股票老虎国际,曼恩凯德生物医疗行情,曼恩凯德生物医疗股票行情,曼恩凯德生物医疗股价,曼恩凯德生物医疗股市,曼恩凯德生物医疗股票价格,曼恩凯德生物医疗股票交易,曼恩凯德生物医疗股票购买,曼恩凯德生物医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"曼恩凯德生物医疗(MNKD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供曼恩凯德生物医疗(MNKD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}